Drug intelligence / Profile preview

gefitinib + irinotecan + paclitaxel

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

This combination involves **gefitinib**, a tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC), **irinotecan**, a topoisomerase I inhibitor used in cancer treatment, and **paclitaxel**, a taxane chemotherapeutic agent. The combination has been studied for its efficacy in treating advanced NSCLC, though results have shown mixed effectiveness.

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)TOP1 (DNA Topoisomerase I)Microtubule

Beyond the preview

Go deeper on gefitinib + irinotecan + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gefitinib + irinotecan + paclitaxel.

Explore the full profile